



# Zion Pharma Announces Sale of Lead Program to Roche

May 11, 2023

**Palo Alto and Shanghai – May 11, 2023** – Cooley advised Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, on the acquisition of its lead program, ZN-A-1041, by Roche. Partners Lila Hope and Yiming Liu led the Cooley team.

Zion's lead program, ZN-A-1041, is an orally administered selective tyrosine kinase inhibitor targeting the human epidermal growth factor receptor 2 (HER2), which has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer. Zion will receive up to \$70 million in upfront and near-term milestone payments after certain milestone events. Zion also is eligible to receive up to \$610 million in additional payments following achievement of certain development, regulatory and sales-based milestone events, as well as tiered royalties on sales.

Zion Pharma is a private, clinical-stage biotechnology company focused on the development of novel, small-molecule, anti-tumoral agents on therapeutic targets that drive tumor inhibition, including ataxia telangiectasia mutated (ATM), Kirsten rat sarcoma (KRAS G12D) and SMARCA2 (BRM).

## About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our [AI Principles](#), may be considered Attorney Advertising and is subject to our [legal notices](#).

---

## Key Contacts

Lila Hope Palo Alto	lhope@cooley.com +1 650 843 5735
Yiming Liu Shanghai	yimingliu@cooley.com +86 21 6030 0668
Aaron Pomeroy Colorado	apomeroy@cooley.com +1 720 566 4108
David Burns Washington, DC	dburns@cooley.com +1 202 728 7147
Amanda Pacheco Palo Alto	apacheco@cooley.com +1 650 843 5957
Chen Chen Palo Alto	chen.chen@cooley.com +1 650 843 5592

---

This information is a general description of the law; it is not intended to provide specific legal advice nor is it intended to create an attorney-client relationship with Cooley LLP. Before taking any action on this information you should seek professional counsel.

Copyright © 2023 Cooley LLP, 3175 Hanover Street, Palo Alto, CA 94304; Cooley (UK) LLP, 22 Bishopsgate, London, UK EC2N 4BQ. Permission is granted to make and redistribute, without charge, copies of this entire document provided that such copies are complete and unaltered and identify Cooley LLP as the author. All other rights reserved.